Randomized, Double Blind Evaluation of Late Boost Strategies for HIV-uninfected Participants in the HIV Vaccine Efficacy Trial RV 144: "Aventis Pasteur Live Recombinant ALVAC-HIV (vCP1521) Priming With VaxGen gp120 B/E (AIDSVAX B/E) Boosting in HIV-uninfected Thai Adults"
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 15 Apr 2017
At a glance
- Drugs HIV gp120 vaccine (Primary) ; HIV vaccine vCP1521 (Primary)
- Indications HIV infections
- Focus Adverse reactions; Pharmacodynamics
- 10 Jun 2017 Biomarkers information updated
- 28 Mar 2017 Planned End Date changed from 1 Dec 2017 to 1 Dec 2018.
- 28 Mar 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Dec 2017.